H.C. Wainwright lowered the firm’s price target on Indaptus Therapeutics to $12 from $15 and keeps a Buy rating on the shares following the Q4 results. The analyst anticipate the company may need to raise additional capital at some point over the course of the next six to nine months.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INDP:
- Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
- Indaptus Therapeutics reports 2022 EPS ($1.73) vs ($1.89) last year
- Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023
- Indaptus Therapeutics activates Emory Winship Cancer Institute as trial site
- Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
